166 related articles for article (PubMed ID: 35449574)
1. Editorial: Advances of Targeted Therapy in Gynecologic Malignancies.
Qiu H; Song K; Wang L; Zhou C
Front Oncol; 2022; 12():887773. PubMed ID: 35449574
[No Abstract] [Full Text] [Related]
2. Immuno-oncology for Gynecologic Malignancies.
How J; Patel A; Jazaeri A
Adv Exp Med Biol; 2020; 1244():149-182. PubMed ID: 32301014
[TBL] [Abstract][Full Text] [Related]
3. Immuno-Oncology for Gynecologic Malignancies.
How JA; Patel A; Jazaeri AA
Adv Exp Med Biol; 2021; 1342():193-232. PubMed ID: 34972966
[TBL] [Abstract][Full Text] [Related]
4. Genomic-Based Therapy of Gynecologic Malignancies.
Markman M
Acta Med Acad; 2019 Apr; 48(1):84-89. PubMed ID: 31264436
[TBL] [Abstract][Full Text] [Related]
5. The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies.
Yahya MA; Sharon SM; Hantisteanu S; Hallak M; Bruchim I
Front Endocrinol (Lausanne); 2018; 9():297. PubMed ID: 29922232
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in Gynecologic Cancers: Are We There Yet?
Pakish JB; Jazaeri AA
Curr Treat Options Oncol; 2017 Aug; 18(10):59. PubMed ID: 28840453
[TBL] [Abstract][Full Text] [Related]
7. Novel Therapies in Gynecologic Cancer.
Bejar FG; Oaknin A; Williamson C; Mayadev J; Peters PN; Secord AA; Wield AM; Coffman LG
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-17. PubMed ID: 35594502
[TBL] [Abstract][Full Text] [Related]
8. New Targeted Therapies and Combinations of Treatments for Cervical, Endometrial, and Ovarian Cancers: A Year in Review.
Gheorghe AS; Dumitrescu EA; Komporaly IA; Mihăilă RI; Lungulescu CV; Stănculeanu DL
Curr Oncol; 2022 Apr; 29(4):2835-2847. PubMed ID: 35448205
[TBL] [Abstract][Full Text] [Related]
9. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review.
Husseinzadeh N; Husseinzadeh HD
Gynecol Oncol; 2014 May; 133(2):375-81. PubMed ID: 24556063
[TBL] [Abstract][Full Text] [Related]
10. The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report.
Yim GW; Suh DH; Kim JW; Kim SC; Kim YT
J Gynecol Oncol; 2019 Jul; 30(4):e91. PubMed ID: 31140217
[TBL] [Abstract][Full Text] [Related]
11. Major clinical research advances in gynecologic cancer in 2015.
Suh DH; Kim M; Kim HJ; Lee KH; Kim JW
J Gynecol Oncol; 2016 Nov; 27(6):e53. PubMed ID: 27775259
[TBL] [Abstract][Full Text] [Related]
12. Outcome of patients with local recurrent gynecologic malignancies after resection combined with intraoperative electron radiation therapy (IOERT).
Arians N; Foerster R; Rom J; Uhl M; Roeder F; Debus J; Lindel K
Radiat Oncol; 2016 Mar; 11():44. PubMed ID: 26988089
[TBL] [Abstract][Full Text] [Related]
13. T-cell target antigens across major gynecologic cancers.
Rodriguez-Garcia A; Minutolo NG; Robinson JM; Powell DJ
Gynecol Oncol; 2017 Jun; 145(3):426-435. PubMed ID: 28377094
[TBL] [Abstract][Full Text] [Related]
14. Optimizing immunotherapy for gynecologic cancers.
Rubinstein MM; Makker V
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):1-8. PubMed ID: 31833942
[TBL] [Abstract][Full Text] [Related]
15. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.
Liu J; Westin SN
Gynecol Oncol; 2016 Apr; 141(1):65-71. PubMed ID: 27016231
[TBL] [Abstract][Full Text] [Related]
16. Clinical statistics of gynecologic cancers in Japan.
Yamagami W; Nagase S; Takahashi F; Ino K; Hachisuga T; Aoki D; Katabuchi H
J Gynecol Oncol; 2017 Mar; 28(2):e32. PubMed ID: 28198168
[TBL] [Abstract][Full Text] [Related]
17. New and Novel Therapies for Gynecologic Cancers.
Richardson DL
Semin Oncol Nurs; 2019 Apr; 35(2):217-219. PubMed ID: 30876683
[TBL] [Abstract][Full Text] [Related]
18. Ethnicity-related trends in gynecologic malignancies in Israel, 1993-2013.
Michaan N; Gortzak-Uzan L; Grisario D; Laskov I
Int J Gynaecol Obstet; 2018 Aug; 142(2):176-181. PubMed ID: 29742279
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of carbohydrate antigen 72-4 combined with carbohydrate antigen 15.3 in ovarian cancer, cervical cancer and endometrial cancer.
Li M; Men X; Zhang X
J BUON; 2020; 25(4):1918-1927. PubMed ID: 33099933
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy and Systemic Therapy in Metastatic/Recurrent Endometrial and Cervical Cancers.
Lima J; Ali Z; Banerjee S
Clin Oncol (R Coll Radiol); 2021 Sep; 33(9):608-615. PubMed ID: 34312021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
